Cargando…
Analytical and Clinical Performance of a Real-time Screening PCR Assay Identifying Congenital CMV Infection
BACKGROUND: Congenital CMV infection (cCMV) is the most common identifiable cause of mental retardation in the United States but requires early diagnosis to define the infection and to institute effective antiviral therapy. Traditional identification strategies including hearing screens and physical...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631887/ http://dx.doi.org/10.1093/ofid/ofx163.861 |
_version_ | 1783269583279357952 |
---|---|
author | Rohde, Benjamin Carillo-Marquez, Maria Tomlinson, Ryan Blanch, Jacqueline Kim-Hoehamer, Young-In Patel, Hema Patel, Chirag Zanalian, Gita Osborne, Gertrude Davis, Joseph Patel, Anami Devincenzo, John P |
author_facet | Rohde, Benjamin Carillo-Marquez, Maria Tomlinson, Ryan Blanch, Jacqueline Kim-Hoehamer, Young-In Patel, Hema Patel, Chirag Zanalian, Gita Osborne, Gertrude Davis, Joseph Patel, Anami Devincenzo, John P |
author_sort | Rohde, Benjamin |
collection | PubMed |
description | BACKGROUND: Congenital CMV infection (cCMV) is the most common identifiable cause of mental retardation in the United States but requires early diagnosis to define the infection and to institute effective antiviral therapy. Traditional identification strategies including hearing screens and physical exams likely miss many patients with cCMV. We therefore developed and evaluated the performance of a PCR assay optimized for low cost, specimen collection at time of dried blood spot collection, and detection thresholds below the salivary CMV concentrations known to occur in cCMV patients. METHODS: We utilized a real-time CMV PCR assay (Simplexa(TM) CMV)(DiaSorin, Cypress CA) amplifying the UL83 gene and the 3M Integrated Cycler. Saliva was collected from volunteers (Copan swab), and spiked with known concentrations of CMV culture supernatant quantified by COBAS Ampliprep(TM). (Roche Diagnostics). Additionally, saliva was collected by copan swab from all births within a single multi-hospital system from 3/21/16 – 5/4/17. Newborns who were initial screen PCR positive were subsequently evaluated by urine CMV PCR by an outside laboratory for confirmation of cCMV. RESULTS: Analytical threshold of detection was well below 4 log copies/ML, with 100% of samples testing positive at 3.5 log copies/ML (Fig 1). 6127 newborn saliva samples were evaluated and 61 were PCR positive (£40 CT). 47 of these tests were confirmed by urine PCR (Fig 2) (PPV 0.9792, NPV 0.9988, Sens 0.8704, Spec 0.9998). Screen positive tests which were not confirmed by urine PCR had CT values £36. Adjusting the definition of a positive to CT £36 further improved the performance (PPV >0.9999, NPV 0.9997, Sens 0.9592, Spec >0.9999). CONCLUSION: We demonstrate good performance of a congenital CMV methodology thus facilitating an effective universal newborn screening program DISCLOSURES: J. P. Devincenzo, AstraZeneca/MedImmune: Investigator, Research support |
format | Online Article Text |
id | pubmed-5631887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56318872017-11-07 Analytical and Clinical Performance of a Real-time Screening PCR Assay Identifying Congenital CMV Infection Rohde, Benjamin Carillo-Marquez, Maria Tomlinson, Ryan Blanch, Jacqueline Kim-Hoehamer, Young-In Patel, Hema Patel, Chirag Zanalian, Gita Osborne, Gertrude Davis, Joseph Patel, Anami Devincenzo, John P Open Forum Infect Dis Abstracts BACKGROUND: Congenital CMV infection (cCMV) is the most common identifiable cause of mental retardation in the United States but requires early diagnosis to define the infection and to institute effective antiviral therapy. Traditional identification strategies including hearing screens and physical exams likely miss many patients with cCMV. We therefore developed and evaluated the performance of a PCR assay optimized for low cost, specimen collection at time of dried blood spot collection, and detection thresholds below the salivary CMV concentrations known to occur in cCMV patients. METHODS: We utilized a real-time CMV PCR assay (Simplexa(TM) CMV)(DiaSorin, Cypress CA) amplifying the UL83 gene and the 3M Integrated Cycler. Saliva was collected from volunteers (Copan swab), and spiked with known concentrations of CMV culture supernatant quantified by COBAS Ampliprep(TM). (Roche Diagnostics). Additionally, saliva was collected by copan swab from all births within a single multi-hospital system from 3/21/16 – 5/4/17. Newborns who were initial screen PCR positive were subsequently evaluated by urine CMV PCR by an outside laboratory for confirmation of cCMV. RESULTS: Analytical threshold of detection was well below 4 log copies/ML, with 100% of samples testing positive at 3.5 log copies/ML (Fig 1). 6127 newborn saliva samples were evaluated and 61 were PCR positive (£40 CT). 47 of these tests were confirmed by urine PCR (Fig 2) (PPV 0.9792, NPV 0.9988, Sens 0.8704, Spec 0.9998). Screen positive tests which were not confirmed by urine PCR had CT values £36. Adjusting the definition of a positive to CT £36 further improved the performance (PPV >0.9999, NPV 0.9997, Sens 0.9592, Spec >0.9999). CONCLUSION: We demonstrate good performance of a congenital CMV methodology thus facilitating an effective universal newborn screening program DISCLOSURES: J. P. Devincenzo, AstraZeneca/MedImmune: Investigator, Research support Oxford University Press 2017-10-04 /pmc/articles/PMC5631887/ http://dx.doi.org/10.1093/ofid/ofx163.861 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Rohde, Benjamin Carillo-Marquez, Maria Tomlinson, Ryan Blanch, Jacqueline Kim-Hoehamer, Young-In Patel, Hema Patel, Chirag Zanalian, Gita Osborne, Gertrude Davis, Joseph Patel, Anami Devincenzo, John P Analytical and Clinical Performance of a Real-time Screening PCR Assay Identifying Congenital CMV Infection |
title | Analytical and Clinical Performance of a Real-time Screening PCR Assay Identifying Congenital CMV Infection |
title_full | Analytical and Clinical Performance of a Real-time Screening PCR Assay Identifying Congenital CMV Infection |
title_fullStr | Analytical and Clinical Performance of a Real-time Screening PCR Assay Identifying Congenital CMV Infection |
title_full_unstemmed | Analytical and Clinical Performance of a Real-time Screening PCR Assay Identifying Congenital CMV Infection |
title_short | Analytical and Clinical Performance of a Real-time Screening PCR Assay Identifying Congenital CMV Infection |
title_sort | analytical and clinical performance of a real-time screening pcr assay identifying congenital cmv infection |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631887/ http://dx.doi.org/10.1093/ofid/ofx163.861 |
work_keys_str_mv | AT rohdebenjamin analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT carillomarquezmaria analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT tomlinsonryan analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT blanchjacqueline analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT kimhoehameryoungin analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT patelhema analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT patelchirag analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT zanaliangita analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT osbornegertrude analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT davisjoseph analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT patelanami analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection AT devincenzojohnp analyticalandclinicalperformanceofarealtimescreeningpcrassayidentifyingcongenitalcmvinfection |